No Free TRIPS Act

The No Free TRIPS Act, also known as Bill 118 s 1834, is a piece of legislation currently being considered by the US Congress. The bill aims to address the issue of intellectual property rights and access to essential medicines during public health emergencies, such as the COVID-19 pandemic.

The bill specifically focuses on the Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement, which is a global agreement that sets out minimum standards for intellectual property protection in trade. The No Free TRIPS Act seeks to ensure that during public health emergencies, countries have the flexibility to waive certain intellectual property rights in order to increase access to essential medicines, vaccines, and medical technologies.

The bill recognizes that intellectual property rights can sometimes hinder access to life-saving treatments, especially in developing countries where affordability is a major concern. By allowing countries to waive certain intellectual property rights during emergencies, the No Free TRIPS Act aims to promote global health equity and ensure that everyone has access to the medical resources they need. Overall, the No Free TRIPS Act is a bipartisan effort to balance the need for intellectual property protection with the need for global health equity. It is currently being debated in Congress and has the potential to have a significant impact on how intellectual property rights are managed during public health emergencies.